PE20211195A1 - Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica - Google Patents

Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica

Info

Publication number
PE20211195A1
PE20211195A1 PE2020000735A PE2020000735A PE20211195A1 PE 20211195 A1 PE20211195 A1 PE 20211195A1 PE 2020000735 A PE2020000735 A PE 2020000735A PE 2020000735 A PE2020000735 A PE 2020000735A PE 20211195 A1 PE20211195 A1 PE 20211195A1
Authority
PE
Peru
Prior art keywords
core
pyycomethycene
therapeutically active
active agent
elastomeric matrix
Prior art date
Application number
PE2020000735A
Other languages
English (en)
Inventor
Manja Ahola
Risto Hakala
Piia Hara
Antti Keinanen
Henriikka Korolainen
Jyrki Pihlaja
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Oy filed Critical Bayer Oy
Publication of PE20211195A1 publication Critical patent/PE20211195A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN METODO PARA MODIFICAR LA LIBERACION DE UN AGENTE TERAPEUTICAMENTE ACTIVO DE UNA MATRIZ ELASTOMERICA, EL CUAL COMPRENDE: A) PROPORCIONAR UN NUCLEO QUE COMPRENDE UNA MATRIZ ELASTOMERICA Y UN AGENTE TERAPEUTICAMENTE ACTIVO TAL COMO INDOMETACINA, DICLOFENACO, PIROXICAM, MELOXICAM Y CETOPROFENO; B) SUMERGIR EL NUCLEO EN UNA SOLUCION DE RECUBRIMIENTO QUE COMPRENDE UN ELASTOMERO QUE CONTIENE 20-35% EN PESO DE UN AGENTE DE RELLENO TAL COMO SILICE, DIOXIDO DE TITANIO, SULFATO DE BARIO, CARBONO Y LAS MEZCLAS DE LOS MISMOS, CALCULADO DE LA CANTIDAD TOTAL DE AGENTE DE RELLENO Y ELASTOMERO; C) CURAR EL NUCLEO SUMERGIDO PARA PROPORCIONAR UN NUCLEO RECUBIERTO; DONDE EL ELASTOMERO COMPRENDIDO EN EL NUCLEO Y EL ELASTOMERO COMPRENDIDO EN LA SOLUCION DE RECUBRIMIENTO SE SELECCIONAN DE POLI(DIMETIL)SILOXANOS, POLIETILENO ACETATOS DE VINILO (EVA), POLIURETANOS (PU), POLIHIDROXIETIL-METACRILATOS (PHEMA) Y POLIMETIL-METACRILATOS (PMMA).
PE2020000735A 2017-09-27 2018-09-19 Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica PE20211195A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17193367 2017-09-27
EP18167014 2018-04-12
PCT/EP2018/075331 WO2019063382A1 (en) 2017-09-27 2018-09-19 METHOD FOR MODIFYING THE RELEASE OF A THERAPEUTICALLY ACTIVE AGENT FROM AN ELASTOMERIC MATRIX

Publications (1)

Publication Number Publication Date
PE20211195A1 true PE20211195A1 (es) 2021-07-01

Family

ID=63592747

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020000735A PE20211195A1 (es) 2017-09-27 2018-09-19 Un metodo para modificar la liberacion de un agente terapeuticamente activo de una matriz elastomerica

Country Status (18)

Country Link
US (1) US11666552B2 (es)
EP (1) EP3687495A1 (es)
JP (1) JP7242648B2 (es)
KR (1) KR20200059224A (es)
CN (1) CN111148507B (es)
AU (1) AU2018340266A1 (es)
BR (1) BR112020005928A2 (es)
CA (1) CA3076768A1 (es)
CL (1) CL2020000778A1 (es)
CO (1) CO2020003454A2 (es)
IL (1) IL272878A (es)
JO (1) JOP20200067A1 (es)
MX (1) MX2020007323A (es)
PE (1) PE20211195A1 (es)
SG (1) SG11202001293SA (es)
TW (1) TW201919587A (es)
UY (1) UY37906A (es)
WO (1) WO2019063382A1 (es)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1222897A (zh) * 1996-03-29 1999-07-14 盖里列奥公司 用于形成光学纤维的可剥离聚酰亚胺涂层之方法
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
AU2002210580A1 (en) 2000-10-20 2002-04-29 Leiras Oy Drug delivery system
US20020136573A1 (en) * 2001-01-25 2002-09-26 Xerox Corporation Infrared curing of fluoroelastomer coatings formed over silicone rubber in a fuser member
WO2005004837A1 (en) * 2003-07-10 2005-01-20 Galen (Chemicals) Limited Intravaginal drug delivery devices
US7914841B2 (en) * 2006-02-09 2011-03-29 Cook Medical Technologies Llc Inline application of coatings
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2140860A1 (en) 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
WO2011156648A1 (en) * 2010-06-09 2011-12-15 President And Fellows Of Harvard College Method for producing films
US9801831B2 (en) * 2010-12-30 2017-10-31 Nanyang Technological University Device for controlled release of a bioactive agent
KR20120135689A (ko) * 2011-06-07 2012-12-17 (주) 태웅메디칼 약물 방출 스텐트 코팅제의 제조방법 및 이에 의해 제조된 약물 방출 스텐트 코팅제
US20130236524A1 (en) 2011-09-09 2013-09-12 Axxia Pharmaceuticals, Llc Silicone coated implant
US9434857B2 (en) * 2011-11-15 2016-09-06 Ethicon, Inc. Rapid cure silicone lubricious coatings
AR089765A1 (es) 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
US20140037964A1 (en) * 2012-08-02 2014-02-06 Haipeng Zheng Optical Article Containing A Self-Healing Coating And Improved Initial Haze
PE20160534A1 (es) 2013-10-18 2016-06-15 Bayer Oy Sistema de administracion intrauterina
LT3247327T (lt) * 2015-01-21 2019-10-10 Bayer Oy Vaisto pateikimo sistema, apimanti nesteroidinį priešuždegiminį (nsaid) ir progestogeninį junginį, ir gamybos būdai
BR112018012743A2 (pt) 2015-12-21 2018-12-04 Bayer Oy método para fabricar um dispositivo de administração de medicamento e um dispositivo de administração de medicamento fabricado de acordo com o método
EP3551280B1 (en) * 2016-12-12 2023-08-09 The Regents of the University of California Implantable and non-invasive stimulators for gastrointestinal therapeutics

Also Published As

Publication number Publication date
CN111148507A (zh) 2020-05-12
IL272878A (en) 2020-04-30
KR20200059224A (ko) 2020-05-28
JP7242648B2 (ja) 2023-03-20
CL2020000778A1 (es) 2020-09-25
JOP20200067A1 (ar) 2020-04-27
EP3687495A1 (en) 2020-08-05
TW201919587A (zh) 2019-06-01
CO2020003454A2 (es) 2020-04-13
US11666552B2 (en) 2023-06-06
CN111148507B (zh) 2023-09-26
SG11202001293SA (en) 2020-03-30
CA3076768A1 (en) 2019-04-04
RU2020113426A3 (es) 2022-02-22
US20200276159A1 (en) 2020-09-03
RU2020113426A (ru) 2021-10-27
BR112020005928A2 (pt) 2020-10-06
AU2018340266A1 (en) 2020-03-05
WO2019063382A1 (en) 2019-04-04
JP2020535159A (ja) 2020-12-03
MX2020007323A (es) 2020-09-07
UY37906A (es) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2016012151A (es) Composiciones termicamente expandibles.
MX2017011184A (es) Proceso para producir un cuerpo curado fotocromico.
AR097032A1 (es) Hidrogeles de poli(alquenilamida)-polisacárido para el tratamiento de formaciones subterráneas
AR095446A1 (es) Métodos para entrecruzar composiciones de polímeros en la presencia de oxígeno atmosférico
UY38160A (es) Partículas implantables y métodos relacionados
BR112017012663A2 (pt) composição de cuidados com o sol, películas de enrijecimento da pele e de cuidados com o sol, e, método para proteger a pele de raios uv.
EP3243884A4 (en) Radiation curable coating composition, low-refractive-index layer, and antireflective film
CR20180228A (es) Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma
AR085096A1 (es) Control de aleurodios
BR112015022625A2 (pt) micromatrizes para entrega de agente terapêutico e métodos de uso
NI201000156A (es) Compuestos heterocíclicos novedosos y usos de los mismos.
WO2013103533A3 (en) Free radical polymerizable compositions comprising ionic silicones
PE20121790A1 (es) Composiciones de liberacion controlada
CL2017002031A1 (es) Formulación en polvo nasal para el tratamiento de hipoglicemia
BR112018009311A8 (pt) ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?
MX2018003725A (es) Composiciones termicamente expandibles que comprenden polisacarido.
CR20150543A (es) Método de tratamiento de páncreas e hígado para condiciones por transplante de células madre en paredes de conducto biliar
AR105350A1 (es) Composición de limpieza con propelente
BR112017023722A2 (pt) composição formadora de película curável, substrato revestido e método para revestir um substrato
CL2018003826A1 (es) Uso de una fracción lignina como un agente anti fitopatogenico y composiciones fitopatogenicas conteniendo dicho agente.
UY35803A (es) Recubrimiento de alginato para tratamiento de esquejes
AR095905A1 (es) Proceso para el entrecruzamiento de elastómeros
BR112013007656A2 (pt) Composição iniciadora de silicone, seus usos e seu método de produção
BR112019023919A2 (pt) cateter de liberação de stent com controle de cursor rápido e roda de acionamento lenta
CL2017000977A1 (es) Método de tratamiento para antibrote de tubérculos con cantidad reducida de cipc